Multiple therapeutic peptide vaccines for patients with advanced gastric cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Oncology

• Publication date

  2017-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ijo.2017.3955PMID 28393243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.

  2016cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• The FDA Guidance on Therapeutic Cancer Vaccines: The Need for Revision to Include Preventive Cancer Vaccines or for a New Guidance Dedicated to Them

  2015cited by this paper
• Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

  2014cited by this paper
• Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

  2014cited by this paper
• Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

  2013cited by this paper
• Overexpression of Forkhead Box M1 Transcription Factor (FOXM1) is a Potential Prognostic Marker and Enhances Chemoresistance for Docetaxel in Gastric Cancer

  2013cited by this paper
• Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

  2013influential reference
• Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma

  2013influential reference
• A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer

  2013cited by this paper
• Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.

  2012cited by this paper
• Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

  2012cited by this paper
• Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.

  2012cited by this paper
• gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

  2012cited by this paper
• Japanese classification of gastric carcinoma: 3rd English edition

  2011cited by this paper
• Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Over‐expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis

  2008cited by this paper
• S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

  2008cited by this paper
• Phase I/II study of ipilimumab for patients with metastatic melanoma.

  2008cited by this paper
• Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer

  2008cited by this paper
• FOXM1, a typical proliferation-associated transcription factor

  2007cited by this paper
• Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.

  2006cited by this paper
• The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.

  2006cited by this paper
• FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells.

  2006cited by this paper
• Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase

  2005cited by this paper
• FoxM1 is required for execution of the mitotic programme and chromosome stability

  2005cited by this paper
• Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe.

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.

  2004cited by this paper
• FOXM1 is a downstream target of Gli1 in basal cell carcinomas.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [Phase I clinical study of oxaliplatin].

  1998cited by this paper
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

  1998cited by this paper
• Phase II study of Taxol in patients with advanced gastric carcinoma.

  1998cited by this paper
• Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293

  1996cited by this paper
• [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].

  1994cited by this paper
• Identification of tumour rejection antigens recognized by T lymphocytes.

  1992cited by this paper

• Exploratory Evaluation of Peptide-Based Immunization Targeting Fusion Glycoprotein-Derived Epitopes of Nipah Virus in Murine Model

  2026influential citation
• KIF20A inhibits TRIM21-dependent ubiquitination of DHX9 to boost SOX2 stability, enhancing OSCC stemness and ferroptosis resistance

  2026cites this paper
• KIF20A drives epithelial cell proliferation and migration in gastric adenocarcinoma, facilitating macrophage M2 polarization and subsequent immune evasion.

  2026cites this paper
• Current and Future Directions in Immunotherapy for Gastrointestinal Malignancies

  2025cites this paper
• Recent research progress and clinical status of immunotherapy for colorectal cancer.

  2025cites this paper
• Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease's Origins, Epidemiology, Classification, Diagnosis, and Treatment Options.

  2025cites this paper
• Advances and challenges in cancer immunotherapy: Strategies for personalized treatment.

  2025cites this paper
• Tumor immunotherapy: past, present, and future

  2025cites this paper
• Breaking Barriers in CRC Immunotherapy: Cutting-Edge Advances in Personalized Peptide Vaccine Development.

  2025cites this paper
• Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy

  2024cites this paper
• Knockdown of CENPF induces cell cycle arrest and inhibits epithelial‑mesenchymal transition progression in glioma

  2024cites this paper
• Personalized cancer vaccine design using AI-powered technologies

  2024cites this paper
• Roles of DEPDC1 in various types of cancer (Review)

  2024cites this paper
• Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective

  2024cites this paper
• FOXM1/DEPDC1 feedback loop promotes hepatocarcinogenesis and represents promising targets for cancer therapy

  2024cites this paper
• A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma

  2024cites this paper
• Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development

  2024cites this paper
• mRNA vaccines in gastric cancer: How close are we?

  2024cites this paper
• New Progress of Immunotherapy in Gastric Cancer

  2023cites this paper
• Research progress on the immune microenvironment and immunotherapy in gastric cancer

  2023cites this paper
• mRNA vaccines in gastric cancer: How close are we?

  2023cites this paper
• Expression, regulating mechanism and therapeutic target of KIF20A in multiple cancer

  2023cites this paper
• KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy

  2023cites this paper
• Application of VEGF/VEGFR peptide vaccines in cancer: a systematic review of clinical trials.

  2023cites this paper
• The Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors

  2023cites this paper
• Research Progress of Immunotherapy for Gastric Cancer

  2023cites this paper
• Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.

  2022cites this paper
• The Human Gut Microbiota and Gastrointestinal Cancer: Current Status and Therapeutic Perspectives

  2022cites this paper
• Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination

  2022cites this paper
• A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma

  2022cites this paper
• A narrative review of the emerging role of lymphocyte antigen 6 complex locus K in cancer: from basic research to clinical practice

  2021cites this paper
• Immunotherapy for gastric cancer: a 2021 update.

  2021cites this paper
• Vaccines targeting angiogenesis in melanoma.

  2021cites this paper
• Peptide‐based therapeutic cancer vaccine: Current trends in clinical application

  2021cites this paper
• Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer

  2021cites this paper
• A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

  2020cites this paper
• Peptide-Based Nanomaterials for Tumor Immunotherapy

  2020cites this paper
• Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]

  2020cites this paper
• Identification of biomarkers in colon cancer based on bioinformatic analysis

  2020cites this paper
• Immunotherapy of Gastric and Esophageal Cancers

  2020cites this paper
• Role of Immunotherapy in Advanced Gastroesophageal Cancer

  2020cites this paper
• Targeting Angiogenesis With Peptide Vaccines

  2019cites this paper
• Immunization using male germ cells and gametes as rich sources of cancer/testis antigens for inhibition of 4T1 breast tumors' growth and metastasis in BALB/c mice.

  2019cites this paper
• Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

  2019cites this paper
• A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

  2018cites this paper
• Uncovering missed indels by leveraging unmapped reads

  2018cites this paper
• Therapeutic cancer vaccines: From initial findings to prospects.

  2018cites this paper
• Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models

  2018cites this paper
• Upregulation of KIF20A correlates with poor prognosis in gastric cancer

  2018cites this paper
• CDK 5 suppresses the metastasis of gastric cancer cells by interacting with and regulating PP 2 A

  2018cites this paper
• CDK5 suppresses the metastasis of gastric cancer cells by interacting with and regulating PP2A

  2018cites this paper
• A universal anti‐cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival

  2018cites this paper
• Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis

  2018cites this paper
• The evolving immunotherapeutic landscape in advanced oesophagogastric cancer

  2018cites this paper
• A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric Cancer.

  2017cites this paper
• Personalized peptide vaccines for cancer therapy: current progress and state of the art

  2017cites this paper